Pluristem Therapeutics Inc. (Nasdaq: PSTI) is TheSUBWAY Stock Pick of the Day

This morning we are featuring Pluristem Therapeutics Inc. (Nasdaq: PSTI), TheSUBWAY is anticipating a significant move to the upside today:

Visit TheSUBWAY Blog Here:
http://stock-promoter.thesubway.com/thesubway-clients/pluristem-therapeutics-inc-nasdaq-psti-is-thesubway-stock-pick-of-the-day/571

News for Pluristem Therapeutics Inc. (Nasdaq:PSTI), Full News can be read here:
http://stock-promoter.thesubway.com/thesubway-clients/pluristem-therapeutics-inc-nasdaqpsti-successfully-concludes-final-pre-clinical-safety-studies-with-plx-pad-in-preparation-for-human-trials/588

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today the successful conclusion of its pre-clinical studies utilizing PLX-PAD prior to the initiation of human clinical trials. PLX-PAD is Pluristem’s cellular product for the treatment of critical limb ischemia (CLI), the end phase of Peripheral Artery Disease (PAD).

The final studies involved 150 animals that received single, repeated intra-muscular (IM) injections of PLX-PAD or a control substance then followed for up to 3 months post-injection. No adverse effects were noted to be caused by the PLX-PAD injections throughout the study period. Moreover, all the histology, hematology and biochemistry panels and biodistribution results support the safe administration of PLX-PAD.

Previously, the Company had reported that in animals whose hind legs were rendered ischemic (reduction in blood flow) using standard industry methodologies, post-treatment evaluation using laser Doppler technology indicated revascularization (return of blood flow) of the limbs treated with PLX-PAD but not in those limbs not treated with PLX-PAD. The affected limbs’ function also improved in those animals receiving PLX-PAD. Additionally, microscopic analyses of those limbs treated with PLX-PAD indicated a statistically significant increase in the number of new capillaries (vessels) supplying the limb, suggesting PLX-PAD has the ability to promote angiogenesis (new vessel formation).

Of significant interest is the fact that the last time the Bollinger Bands were this tight and Pluristem Therapeutics Inc. (Nasdaq: PSTI) put out news, the stock jumped, CLOSING UP OVER 45 PERCENT FOR THE DAY:

The history for Pluristem Therapeutics Inc. (Nasdaq: PSTI) can be seen in the following link:
http://www.thesubway.com/companydata.asp?qm_page=9071

We are strongly anticipating a considerable move higher this morning in Pluristem Therapeutics Inc. (Nasdaq: PSTI) due to this combination of News & Bollinger Bands.   

Our PHILS X1 chart is showing support to be right under Pluristem Therapeutics Inc. (Nasdaq: PSTI) at $.96 and resistance at $1.10.  This is an excellent risk of losing 3% vs. a possible reward of over 10%.  We are also anticipating a substantially higher move in Pluristem Therapeutics Inc. (Nasdaq: PSTI) based off this News / Bollinger Band combination, mentioned above:

There is a lot of volatility in Pluristem Therapeutics Inc. (Nasdaq: PSTI), but for a trader this is an excellent opportunity.  Our Daily chart and 15 Minute chart are showing a lot of volatily so we would recommend using trailing stops with Pluristem Therapeutics Inc. (Nasdaq: PSTI):

Our Weekly chart has been on the bottom for a period of time.  Pluristem Therapeutics Inc. (Nasdaq: PSTI) has been bouncing off it’s current level and we anticipate another bounce off this level this morning:

Finally, we are not seeing institutional buying in Pluristem Therapeutics Inc. (Nasdaq: PSTI) with our PHILS X2 chart, which turns blue when institutions are buying & brown when institutions are selling, but the last time there was News with the Bollinger Bands this close institutions did get into Pluristem Therapeutics Inc. (Nasdaq: PSTI) and the stock CLOSED UP OVER 45 PERCENT FOR THE DAY:

Keep your stop tight in Pluristem Therapeutics Inc. (Nasdaq: PSTI) and we would be using an initial stop at or just under the $.96 level, which we would make a tight trailing stop as Pluristem Therapeutics Inc. (Nasdaq: PSTI) started to move higher.  Good Luck Trading!

TheSubway.com acknowledges and thanks the principles of www.philsgang.com site for their permission in allowing us the use and demonstration of the their Phil’s X-1 and Phil’s X-2 charting software.

Full disclosure: Long at time of writing   -   Disclosure of Conflicts of Interest

All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRGP may have been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP’s Licensors, affiliates, officers, directors and employees may own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value.